IQVIA Holdings Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From IQVIA Holdings Inc.
Second quarter performance was better than expected, but commercial weaknesses show the need for R&D wins and M&A deals as Tecfidera generics and aducanumab uncertainty weigh on the company.
COVID-19 has generated a mind-boggling one billion-plus mentions on social media, unleashing unstructured big data rich in insights. Experts explain why pharma may well want to“listen in” more raptly to such conversations across therapy areas while shaping some aspects of business strategy.
As agency prepares to hear from stakeholders on its strategy, real-world data precedents already are being set thanks to COVID-19, Aetion tells the Pink Sheet.
While the main role of SARS-CoV-2 antibody testing is currently limited to determining exposure to the virus in populations, the scientific community is working hard to define the neutralizing properties of the antibodies detected, and the duration of the immune response. As a result, antibody testing could be here to stay for the long term for monitoring populations, testing vaccines and selecting patients for trials of a variety of new therapies to treat numerous conditions.
- Contract Research, Toxicology Testing-CRO
- Other Names / Subsidiaries
- IMS Health, IQVIA Biotech LLC, Novasyte, LLC